Non-epithelial ovarian tumours consist of sex cord-stromal tumours (SCSTs), germ cell tumours (GCTs), as well as other miscellaneous neoplasms such as lymphomas and soft tissue tumours ([Table 1](#tbl1){ref-type="table"} ([@bib26])). Sex cord-stromal tumours and GCTs, respectively, comprise 8% and 3% of all ovarian malignancies in Western countries ([@bib28]; [@bib30]; [@bib16]). Although SCSTs can arise in women of all ages ([@bib30]), GCTs often develop in adolescence or early adulthood and almost 70% of ovarian tumours occurring before the age of 20 years are germ cell in type ([@bib16]). GCTs can arise in both male and female patients; in adults, 90% develop in the gonad and the other 10% arise extra-gonadally, while in children, the tumours arise in gonadal and extra-gonadal sites with similar frequency ([@bib9]; [@bib2]). These tumours are sub-classified depending on the degree and direction of differentiation: germinomas (dysgerminomas in the ovary and seminomas in the testis), embryonal carcinomas, yolk sac tumours (also known as an endodermal sinus tumour), polyembryomas, choriocarcinomas, teratomas (mature and immature) and mixed malignant GCTs, which are composed of more than one tumour type ([Table 1](#tbl1){ref-type="table"} ([@bib26])). Sex cord-stromal tumours are further categorised into granulosa-stromal cell tumours, Sertoli-stromal cell tumours (including Sertoli--Leydig cell tumours (SLCTs)), mixed and unclassified SCST, and steroid cell tumours ([Table 1](#tbl1){ref-type="table"} ([@bib26])). The prognosis of SCSTs and GCTs is generally favourable, with an overall survival of 89% and 80%, respectively ([@bib24]; [@bib18]).

In addition to these non-epithelial tumours, other very rare and highly malignant ovarian tumours exist that fall under the 'miscellaneous tumours\' category, with some categorised as small round cell tumours of childhood ([@bib26]). These include, but are not limited to, small-cell carcinoma of the ovary, hypercalcaemic type and rhabdomyosarcoma ([Table 1](#tbl1){ref-type="table"}). Owing to the rarity of these tumours, they are difficult to comprehensively study and little is known about their biology or genetics.

DICER protein, encoded by the *DICER1* gene, has many functions, including virus and transposon defence, chromatin regulation, centromere integrity and most notably, control of gene expression as part of the microRNA (miRNA) pathway ([@bib19]). MiRNAs are small (20--22 nucleotide) non-coding RNAs that regulate the translation of downstream target genes at their 3′-untranslated region and, as such, have an important role in virtually all biological processes. A mutation in any component of the miRNA processing pathway can potentially modify the expression of miRNAs, causing dysregulation of their target mRNA expression. MiRNAs are generally downregulated in cancer ([@bib17]) and have been shown to function as both oncogenes and as tumour suppressors in their own right. As a member of the RNase III endonuclease family, DICER measures and cleaves all precursor miRNAs into mature miRNAs, and hence is an essential part of this pathway.

In recent years, the role of DICER in cancer progression and prognosis has been extensively studied. In several cancers, including lung, breast, ovarian and endometrial carcinoma, low levels of DICER expression are associated with poorer survival rates. Conversely, in prostate and colorectal cancers, higher expression of DICER has been shown to be associated with a worse prognosis ([@bib4]). *DICER1* is the only gene in the miRNA pathway in which germline mutations predispose to a Mendelian disorder, which is characterised by a range of mainly paediatric-onset cancers ([@bib4]). Germline mutations were first discovered in patients with pleuropulmonary blastoma (PPB), a rare lung tumour, who all had a family history of PPB or the related familial tumour dysplasia syndrome (PPB-FTDS, Online Mendelian Inheritance in Man (OMIM) number, 601200 ([@bib12])). This syndrome commonly includes cystic nephroma, ovarian SCSTs (particularly SLCTs), and multinodular goitre ([@bib4]). Since then, additional rare neoplasms have been included in the DICER1 syndrome, when they were shown to be associated with deleterious germline *DICER1* mutations, including cervical embryonal rhabdomyosarcoma (ERMS), ciliary-body medulloepithelioma, pituitary blastoma, cervical primitive neuroectodermal tumour, juvenile intestinal hamartomatous polyps and Wilms tumour ([@bib8]; [@bib27]; [@bib6]).

Somatic mutations in *DICER1* exist in the tumours of many of the patients who harbour germline mutations in this gene: such mutations were found in 30 of 102 (29%) of non-epithelial ovarian tumours. These somatic mutations affected the metal-binding sites of the RNase IIIb domain, and have been named 'hotspots\' ([@bib11]). Furthermore, four of the patients with hotspot mutations from whom constitutional DNA was tested harboured an additional deleterious germline mutation.

Given that in the previous paper, discovery-based whole-exome sequencing of 14 non-epithelial ovarian tumours revealed deleterious somatic mutations only in the RNase III domains of *DICER1* ([@bib11]), and that a previous study, in which the entire *DICER1* gene was sequenced in 191 sporadic Wilms tumours, reported that three of the five identified missense mutations were in the RNase IIIb domain ([@bib29]), we accordingly focussed on the RNase III domains only. We sequenced the RNase IIIa and IIIb domains of *DICER1* in 154 non-epithelial ovarian and testicular tumours and in 43 extra-gonadal GCTs. In doing so, we provide a comprehensive follow-up of the initial study ([@bib11]). In sequencing a wide variety of tumour types, we refine the previous results, extend the phenotypes associated with somatic *DICER1* mutations in non-epithelial gonadal tumours and provide new data on the prevalence of *DICER1* mutations in these and other related tumours, such as extra-gonadal GCTs, ERMS and small-cell carcinoma of the ovary, hypercalcaemic type.

Materials and Methods
=====================

Samples
-------

The study was approved by the relevant institutional review boards: KEMH Ethics Board, WA on 18/06/2012, reference 1986/EW in Perth, the Multicenter Research Ethics Committee (ref: 02/4/071) and Local Research Ethics Committee (ref: 01/128) in Cambridge, the ethics board of the Heinrich-Heine-University in Düsseldorf, and the Institutional Review Board of the Faculty of Medicine of McGill University no. A00-M117-11A in Montreal. Participants provided written informed consent where applicable. Samples were acquired and tested in accordance with approvals obtained at the aforementioned sites. Eighty-six DNA samples from formalin-fixed paraffin-embedded (FFPE) gonadal tumours and 69 DNA samples from fresh-frozen gonadal tumours, as well as 32 constitutional DNA samples from these patients were collected and analysed ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}). Of the total 154 gonadal tumours, 135 occurred in patients that were phenotypically female ([Table 2a](#tbl2a){ref-type="table"}) and 19 arose in those that were phenotypically male ([Table 2b](#tbl2b){ref-type="table"}). In addition, as few genetic studies have been performed on extra-gonadal GCTs, 43 extra-gonadal GCTs were analysed from 17 male and 26 female patients ([Supplementary Figure S2](#sup1){ref-type="supplementary-material"}). Furthermore, eight miscellaneous ovarian tumours were studied: seven cases of small-cell carcinoma of the ovary, hypercalcemic type and one ERMS. All tumours were reviewed by pathologists at the institution from which the samples were acquired or by central reference pathologists ([Supplementary Table S1](#sup1){ref-type="supplementary-material"} and [Supplementary Materials](#sup1){ref-type="supplementary-material"}). The gonadal tumour types analysed are summarised in [Tables 2a and b](#tbl2a){ref-type="table"}.

DNA extraction and Sanger sequencing
------------------------------------

DNA was extracted from FFPE tumour samples using 3--5 slides of 10 *μ*m thick tumour tissue with the QIAamp DNA FFPE Tissue Kit (QIAGEN, Toronto, ON, Canada) according to protocol. DNA from fresh-frozen tumour tissues was extracted using the DNeasy Blood and Tissue Kit (QIAGEN, Hilden, Germany). Sanger sequencing was used to screen the RNase IIIa and IIIb domains of *DICER1* in the tumour samples. Primer pairs for PCR amplification and sequencing were designed using Primer3 (<http://frodo.wi.mit.edu/>) to flank exons ([Supplementary Materials](#sup1){ref-type="supplementary-material"}). The sequences were then filtered using OligoCalc software ([@bib14]) to avoid hairpin formation and UCSC *in silico* PCR software to ensure yield of a single product. DNA from any FFPE sample in which a mutation was found was extracted twice independently and the PCR was repeated at least twice from each independent extraction using QIAGEN HotStarTaq, 10 mM dNTP and 10 × PCR buffer reagents with 1.4 *μ*l of 20 μM primers in a 50-*μ*l reaction. Thermocycler parameters can be found in the [Supplementary Materials](#sup1){ref-type="supplementary-material"}. PCR products were purified and sequenced by conventional Sanger methods by the McGill University and Genome Quebec Innovation Centre. Sequences were analysed visually using Lasergene Version 10 (DNASTAR, Madison, WI, USA).

Results
=======

Using Sanger sequencing, we analysed the RNase III domains of *DICER1* in 154 gonadal tumour samples of various types ([Tables 2a and b](#tbl2a){ref-type="table"}) and in 43 extra-gonadal tumours ([Supplementary Figure S2](#sup1){ref-type="supplementary-material"}). We found 14 heterozygous mutations in *DICER1* affecting five different residues of RNase IIIb: E1705, D1709, E1788, D1810 and E1813 ([Figure 1](#fig1){ref-type="fig"}, [Table 3](#tbl3){ref-type="table"}). Although most of the codon changes were predicted to cause a non-synonymous amino-acid change, one variant (c.5438A\>G) was recently shown to cause skipping of the entire exon 25, leading to a frameshift (p.E1788fsX41) ([@bib29]). Matched constitutional DNA was not available for most tumours with mutations but in all five patients whose constitutional DNA was tested, the mutations were somatic.

The majority of mutations (8/14) were detected in ovarian SLCTs. One other mutation was observed in an unclassified SCST. Five mutations were found in gonadal GCTs (three females and two males). One of these mutations was in a yolk sac tumour (male), one in a mixed dysgerminoma/gonadoblastoma (mostly dysgerminoma, female) and three in mixed malignant GCTs, two of which had a yolk sac tumour component (both females). Three of the five mutated GCTs harboured the same variation (c.5438A\>G). No mutations were detected in any of the 43 extra-gonadal GCTs, in seven cases of small-cell carcinoma of the ovary, hypercalcaemic type or in the single case of ovarian ERMS. There was no significant difference between the ages of the patients with *DICER1* mutations (median age 18, range 20 months--54 years) and those without (median age 17 years, range birth--66 years), (*P*=0.72, Student\'s two-tailed *t*-test). The results are summarised in [Tables 2a and b](#tbl2a){ref-type="table"} and [Supplementary Table S1](#sup1){ref-type="supplementary-material"}.

Discussion
==========

*DICER1* mutations in non-epithelial gonadal tumours
----------------------------------------------------

We found mutations in the RNase IIIb region of *DICER1* in 8 of 15 (53%) of ovarian SLCTs and in 14 of 154 (9%) of all gonadal tumours studied. Our results in SLCTs are consistent with the previous study ([@bib11]), in which *DICER1* hotspot mutations were identified in 26/43 SLCTs (60%). We also analysed seven unclassified SCSTs, and found one mutation. This demonstrates that in tumours where histological classification is difficult, such as in some undifferentiated SCSTs, mutation analysis may aid tumour classification. In addition, we tested seven cases of small-cell carcinoma of the ovary, hypercalcaemic type and one case of ovarian ERMS, but did not find any *DICER1* hotspot mutations. Our study also included extra-gonadal GCTs and a large series of ovarian GCTs of different histological types, and therefore we were able to expand upon earlier findings in these tumours.

[@bib11] identified mutations in 2/15 ovarian yolk sac tumours, whereas we did not find mutations in any of the 20 cases that we studied. However, our two *DICER1*-mutated mixed malignant ovarian GCTs did contain yolk sac components. Consistent with the findings of [@bib11], we analysed 44 dysgerminomas (five of which were associated with gonadoblastoma) and found only a single mutation, allowing us to conclude that mutations in *DICER1* hotspot mutations are rare in dysgerminomas but do occasionally occur.

Another recent study reported that somatic *DICER1* mutations in testicular GCTs are rare ([@bib7]). Although [@bib11] found a hotspot mutation in 1/14 testicular GCTs analysed, [@bib7] identified a mutation in just 1/96 tumours. In comparison, mutations were present in 2/19 testicular GCTs (one YST, one mixed malignant GCT) in the present series. Therefore, overall, somatic hotspot mutations in *DICER1* have been identified in 4/129 (3%) testicular GCTs investigated to date.

Sex cord-stromal tumours, GCTs and the *DICER1* syndrome
--------------------------------------------------------

As the discovery of the *DICER1* syndrome in patients with PPB, several studies have demonstrated the association between germline *DICER1* mutations and various types of ovarian SCSTs and GCTs ([@bib22]; [@bib25]; [@bib27]). SLCTs are by far the most common non-epithelial ovarian tumour associated with the *DICER1* syndrome, and it is not clear whether germline *DICER1* mutations predispose to GCTs. Before identification of the responsible gene, a study described two families in which relatives of patients with PPB were diagnosed with testicular GCTs ([@bib21]). Furthermore, 1 dysgerminoma and 3 seminomas have been reported in relatives of patients with *DICER1* germline mutations ([@bib25]), but no *DICER1* germline mutation was found in the only seminoma patient for which genetic information was available. Moreover, full sequencing of *DICER1* has revealed only a single SNV resulting in p.Q1580H in 228 probands with a GCT, at least 171 of whom had a positive family history of GCT ([@bib27]; [@bib23]). All but one of the mutations we found were in either a tumour definitely associated with the *DICER1* syndrome (SCSTs), or in a GCT with a dysgerminoma or yolk sac component. It remains unclear whether somatic *DICER1* mutations can be causally related to dysgerminomas or pure yolk sac tumours, but if they are, the mutations occur substantially less frequently than in SCSTs, and germline mutations in *DICER1* are rarely associated with susceptibility to GCTs.

Mechanism of tumorigenesis
--------------------------

As previously reported, the mutations we found were clustered around the Mg^2+^ metal-binding sites of the RNase IIIb domain ([@bib11]). However, although these authors detected more mutations at D1709, we found that the majority occurred at D1810 and E1813. It was originally believed that *DICER1* mutations induced neoplasia via a haploinsufficient mechanism ([@bib15]), but more recent studies have shown that some patients with deleterious mutations on one allele of the gene also have a somatic, non-truncating, mutation on the other allele ([@bib11]; [@bib29]). The specific locations of the mutations are more reminiscent of dominantly-acting oncogenes and it is likely that the hotspot-mutated alleles produce a viable, albeit dysfunctional, protein ([@bib11]). As the RNase IIIb domain requires the binding of two Mg^2+^ ions to catalyse the cleavage of the miRNA, improper binding due to an amino-acid change at any of these sites would presumably prevent DICER from processing its target miRNA. Recently, a model has been proposed whereby 5p strand miRNAs are not produced if the DICER protein is mutated at the RNase IIIb domain ([@bib1]). As 5p strand miRNAs are more abundant than 3p strand miRNAs in targeting human mRNAs, loss of the former is likely to lead to increased levels of key proto-oncogenic mRNAs, potentiating tumour development ([@bib1]).

This model may explain how such mutations result in tumorigenesis, but questions still remain as to (1) why germline *DICER1* mutations predispose to highly specific types of very rare cancers and (2) how identical somatic mutations can cause various different types of benign and malignant tumours. It has been suggested that as many of the tumours related to the *DICER1* syndrome possess an embryonal or primitive appearance, perhaps the effect of germline mutations is restricted to certain cell types during development ([@bib11]). The tumours associated with *DICER1* syndrome often occur in younger children, suggesting a developmental relationship. However, the contribution of *DICER1* mutations to the different tumours of the syndrome is variable. Although germline *DICER1* mutations may contribute significantly to cystic nephroma and SLCTs ([@bib3]; [@bib27]), they do not have as great an impact on the occurrence of Wilms tumour ([@bib3]; [@bib27]; [@bib29]). DICER-null embryonic stem cells usually do not survive, but several cell-type specific conditional *DICER1* knockout models exist and experiments suggest that only a subset of differentiated cells are tolerant to a complete loss of *DICER1* ([@bib10]; [@bib13]; [@bib20]). It is plausible that the tissues in which tumours develop more frequently rely more on the function of DICER and miRNAs during development. Indeed, DICER has been shown to be necessary for postnatal differentiation and development of Müllerian duct mesenchyme-derived tissues of the female reproductive tract ([@bib10]), as well as for nephrogenic development ([@bib20]).

Genetic studies such as those described in the current paper are important in potentially modifying or furthering tumour classification, as some tumours with similar histological appearances may have distinct genetic alterations. In the present study, one mutation-positive tumour had been diagnosed as an unclassified SCST, but it is possible that this tumour was in fact a poorly differentiated SLCT. There is a constant evolution in the classification of neoplasia, and the identification of specific molecular abnormalities has the potential to enhance diagnostic accuracy and, ultimately, provide a rational approach to the development of novel treatment strategies ([@bib5]). With advances in targeted therapies, it is likely that the identification of molecular alterations in gonadal SCSTs and GCTs will have increasing impact on diagnosis, treatment and outcome.

The two main limitations of our study were the small sample size for some of the histological subtypes, and the inability to test germline DNA in all of the patients with mutation-positive tumours to determine whether the identified mutations were germline or somatic events.

Conclusion
==========

Through Sanger sequencing of 154 non-epithelial ovarian and testicular tumours, *DICER1* mutations were detected in 8/15 SLCTs, but only a small number of mutations in other types of tumours. Our data, when combined with the only previous publication on this subject ([@bib11]), demonstrate that 34/58 SLCTs (59%) possess RNase IIIb *DICER1* mutations. Due to the heterogeneous nature of SCSTs, the genetic differences between the tumours may aid in classification and provide new therapeutic approaches. A mutation was identified in one unclassified SCST, demonstrating that genetic testing may aid in the diagnosis of histologically problematic or previously unclassifiable tumour types.

The exact function of the observed *DICER1* mutations in the formation and progression of neoplasms presenting in patients with the *DICER1* syndrome remains unknown. If aberrant miRNAs have a more general causal role in these tumours, it is possible that the tumours without *DICER1* mutations have alterations in other factors in the miRNA processing pathway. Further investigations are likely to shed light on the exact role of these *DICER1* mutations in the formation of these rare tumours and other types of neoplasia, whether it be via miRNA maturation or through other *DICER1*-related functions.
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![**Diagram of DICER protein and representative SLCT with mutation.** (**A**) Example of poorly differentiated SLCT harbouring a hotspot mutation in *DICER1*, 20 × . (**B**) Top: hotspot mutation c.5437G\>A found in (**A**), \* denotes mutation. Bottom: wild-type. (**C**) Schematic of DICER protein (NP_001258211.1), listing all predicted amino-acid changes found in analysed samples. Numbers indicate amino-acid position.](bjc2013637f1){#fig1}

###### Classification of non-epithelial and miscellaneous gonadal tumours

  ------------------------------------------------------------
  **Sex cord-stromal tumours**
  **Granulosa-stromal cell tumours**
   Granulosa cell tumour
   Adult type
   Juvenile type
   Thecoma-Fibroma group
   Thecoma
   Fibroma-fibrosarcoma
   Sclerosing stromal tumour
  **Sertoli-stromal cell tumours**
   Sertoli cell tumour
   Stromal-Leydig cell tumour
   Sertoli--Leydig cell tumour (androblastoma)
  **Sex cord-stromal tumours of mixed or unclassified type**
   Sex cord-tumour with annular tubules
   Gynandroblastoma
   Sex cord-stromal tumour, unclassified
  **Steroid cell tumours**
   Leydig cell tumours
   Hilus cell tumour
   Leydig cell tumour, non-hilar type
  **Germ cell tumours**
  **Primitive germ cell tumours**
   Dysgerminoma
   Yolk sac tumour
   Embryonal carcinoma
   Polyembryoma
   Choriocarcinoma
  **Teratoma**
   Mature
   Immature
  **Monodermal and highly specialised types**
  **Mixed germ cell tumours**
  **Germ cell sex cord-stromal tumours**
   Gonadoblastoma
   Mixed germ cell-sex cord-stromal tumour
  **Miscellaneous ovarian tumours**
   Small cell carcinoma, hypercalcaemic type
   Wilms tumour
   Soft tissue tumours not specific to the ovary
   Embryonal rhabdomyosarcoma
  ------------------------------------------------------------

Adapted from [@bib26].

###### Ovarian tumours: histologial subtypes and frequency of DICER1 mutations

  **Tumours studied**                                       **Samples with mutation/total cases studied (%)**
  -------------------------------------------------------- ---------------------------------------------------
  Sex cord-stromal tumours[a](#t2a-fn1){ref-type="fn"}                          9/28 (32)
  Sertoli--Leydig cell tumour                                                   8/15 (53)
  Juvenile granulosa cell tumour                                                   0/4
  Unclassified sex cord-stromal tumour                                          1/7 (14)
  Leydig cell tumour                                                               0/1
  Sex cord-stromal tumour with annular tubules                                     0/1
  Germ cell tumours[b](#t2a-fn2){ref-type="fn"}                                 3/99 (3)
  Teratoma---mature                                                                0/5
  Teratoma---immature                                                             0/15
  Yolk sac tumour                                                                 0/20
  Embryonal carcinoma                                                              0/1
  Mixed malignant germ cell tumour                                              2/14 (17)
  Dyserminoma/gonadoblastoma                                                    1/5 (20)
  Dysgerminoma                                                                    0/39
  Miscellaneous[c](#t2a-fn3){ref-type="fn"}                                        0/8
  Embryonal rhabdomyosarcoma                                                       0/1
  Small-cell carcinoma of the ovary, hypercalcaemic type                           0/7
  Total                                                                        12/135 (9)

Ages 7 months to 66 years (median age 16 years).

Ages birth to 39 years (median age 17 years).

Ages 15 to 46 years (median 18 years).

###### Testicular tumours: histologial subtypes and frequency of DICER1 mutations

  **Tumours studied**                             **Samples with mutation/total cases studied (%)**
  ----------------------------------------------- ---------------------------------------------------
  Germ cell tumours[a](#t2b-fn1){ref-type="fn"}   2/19 (10)
  Teratoma---mature                               0/2
  Teratoma---immature                             0/1
  Yolk sac tumour                                 1/7 (14)
  Embryonal carcinoma                             0/1
  Mixed malignant germ cell tumour                1/5 (20)
  Seminoma                                        0/3
  Total                                           2/19 (10)

Ages 10 months to 25 years (median age 17 years).

###### Summary of all mutations found

  **Codon change**                                         **Tumour types**                    **Age of patient in years (gender)**   **Protein change**    **Previously reported (tumour types)**
  -------------------------------------- ---------------------------------------------------- -------------------------------------- -------------------- -------------------------------------------
  c.5113G→A                                               Unclassified SCST                                   54 (F)                       p.E1705K               Yes (ERMS, SLCT) ([@bib11])
  c.5125G→A                                                      SLCT                                         21 (F)                       p.D1709N             Yes (SLCT,TGCT,YST) ([@bib11])
  c.5428 G→T                                              Mixed GCT (YST/IT)                                  27 (F)                       p.D1810Y        Yes (SLCT, ERMS, MT) ([@bib11], [@bib29])
  c.5429A→G[a](#t3-fn2){ref-type="fn"}            Mixed gonadoblastoma/dysgerminoma                           15 (F)                    p.E1788fs\*41                         No
  c.5429A→T                                          SLCT with components of JGCT                             16 (F)                       p.D1810V                           No
  c.5437G→A                                                      SLCT                                         32 (F)                       p.E1813K                  Yes (SLCT) ([@bib11])
  c.5437G→C                                                      SLCT                                         13 (F)                       p.E1813Q                       Yes (SLCT)
                                                                 SLCT                                         20 (F)                                                       [@bib11])
  c.5438A→G[b](#t3-fn3){ref-type="fn"}               Mixed GCT (dysgerminoma/YST)                             9 (F)                     p.E1788fs\*41                           
                                          Mixed GCT (embryonal carcinoma/IT/choriocarcinoma)                  12 (M)                                                    Yes (SLCT, WT)
                                                                 YST                                          1 (M)                                                  ([@bib11]; [@bib29])
                                                                 SLCT                                         24 (F)                                                            
  c.5439G→C                                                      SLCT                                         16 (F)                       p.E1813D                           No
                                                                 SLCT                                         30 (F)                                                            

Abbreviations: ERMS=embryonal rhabdomyosarcoma; F=female; IT=immature teratoma; JGCT=juvenile granulosa cell tumour; M=male; MT=mature teratoma; SCST=sex cord-stromal tumour; SLCT=Sertoli--Leydig cell tumour; WT=Wilms tumour; YST=yolk sac tumour.

Codon change is at D1810 but causes an A to G substitution causes a skip of exon 25 (unpublished data, Foulkes lab).

Codon change is at E1813 but causes an A to G substitution causes a skip of exon 25.
